Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-23T15:58:54.890Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacologic Treatment Strategies for Sexual Dysfunction in Patients with Epilepsy and Depression

Published online by Cambridge University Press:  07 November 2014

Glen L. Stimmel  and
Mary A. Gutierrez
Glen L. Stimmel*
Affiliation:
Dr. Stimmel is professor of clinical pharmacy, psychiatry, and behavioral sciences at the, University of Southern California Schools of Pharmacyand Medicine in Los Angeles, California
Mary A. Gutierrez
Affiliation:
Dr. Gutierrez is associate professor of clinical pharmacy at the, University of Southern California School of Pharmacy in Los Angeles, California
*
Glen L. Stimmel, PharmD, USC School of Pharmacy, 1985 Zonal Ave, Los Angeles, CA 90089-9121; Tel: 323-442-1463; Fax: 323-442-1681; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Sexual dysfunction is a frequently encountered comorbid condition in patients with many medical and psychiatric conditions, such as epilepsy and depression. Most depressed patients experience some type of sexual dysfunction, decreased sexual desire being the most common. The association of sexual dysfunction with epilepsy is less clear. Changes in sex hormone levels are common in patients with epilepsy and may be attributable to the disease or to antiepileptic drugs (AEDs). Sexual dysfunction associated with depression or epilepsy is generally treated according to standard guidelines for the management of sexual disorders, since data from special populations are not available. The most common forms of female sexual dysfunction are lack of sexual desire and difficulty achieving orgasm. There are no approved pharmacotherapies for female hypoactive sexual desire disorder or female orgasmic disorder. Female sexual arousal disorder is treated with estrogen replacement therapy when indicated or vaginal lubricants. The most common male sexual dysfunction disorders are premature ejaculation and erectile dysfunction.  Phosphodiesterase type-5 inhibitor drugs are now the first-line treatment for erectile dysfunction, and selective serotonin reuptake inhibitors and topical anesthetic creams are nonapproved but effective treatments for premature ejaculation. Testosterone and aromatase inhibitors have been used investigationally to treat sexual dysfunction in men taking AEDs. Patient education and follow-up appointments are essential to ensure optimal outcomes of pharmacologic treatments for sexual dysfunction.

Type
Research Article
Information
CNS Spectrums , Volume 11 , Issue S9 , 2006 , pp. 31 - 37
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Kanner, AM. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol Psychol. 2003;54:388–398.CrossRefGoogle ScholarPubMed
2.Fourcroy, JL. Female sexual dysfunction: potential for pharmacotherapy. Drugs. 2003;63:1445–1457.CrossRefGoogle ScholarPubMed
3.Laumann, EO, Paik, A, Rosen, RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281:537–544.CrossRefGoogle ScholarPubMed
4.Lewis, RW, Fugl-Meyer, KS, Bosch, R, et al.Epidemiology/risk factors of sexual dysfunction. J Sex Med. 2004;1(1):35–39.CrossRefGoogle ScholarPubMed
5.Seagraves, RT. Female sexual disorders: psychiatric aspects. Can J Psychiatry. 2002;47:419–425.CrossRefGoogle Scholar
6.Sadovsky, R, Stimmel, GL. A focus on premature ejaculation. Drug Topics. 2005;1(suppl):1–16.Google Scholar
7.Rowland, D, Perelman, M, Altof, S, et al.Self-reported premature ejaculation and aspects of sexual functioning and satisfaction. J Sex Med. 2004;1:225–232.CrossRefGoogle ScholarPubMed
8.Feldman, HA, Goldstein, I, Hatzichristou, DG, et al.Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61.CrossRefGoogle ScholarPubMed
9.Diagnostic and Statistical Manual of Mental Disorders. 4th ed text rev. Washington DC: American Psychiatric Association; 2000.Google Scholar
10.Baldwin, DS. Depression and sexual dysfunction. Br Med Bull. 2001;57:81–99.CrossRefGoogle ScholarPubMed
11.Kennedy, SH, Dickens, SE, Eisfeld, BSet al.Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord. 1999;56:201–208.CrossRefGoogle ScholarPubMed
12.Araujo, AB, Durante, R, Feldman, HA, et al.The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med. 1998;60:458–465.CrossRefGoogle ScholarPubMed
13.Penovich, PE. The effects of epilepsy and its treatment on sexual and reproductive function. Epilepsia. 2000;41(suppl 2):S53–S61.CrossRefGoogle ScholarPubMed
14.Rattya, J, Turkka, J, Pakarinen, AJ, et al.Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology. 2001;56:31–36.CrossRefGoogle ScholarPubMed
15.Isojarvi, JIT, Repo, M, Pakarinen, AJet al.Carbamazepine, phenytoin, sex hormones, and sexual function in men with epilepsy. Epilepsia. 1995;36(4):366–370.CrossRefGoogle ScholarPubMed
16.Duncan, S, Balcklaw, J, Beastall, GH, Brodie, MJ. Sexual function in women with epilepsy. Epilepsia. 1997;38:1074–1081.CrossRefGoogle ScholarPubMed
17.Morrell, MJ, Guldner, GT. Self-reported sexual function and sexual arousability in women with epilepsy. Epilepsia. 1996;37:1204–1210.CrossRefGoogle ScholarPubMed
18.Hatzichristou, D, Rosen, RC, Broderick, G, et al.Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med. 2004;1:49–57.CrossRefGoogle ScholarPubMed
19.McCullough, AR, Barada, JH, Fawzy, A, et al.Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology. 2002;60(suppl 2B):28–38.CrossRefGoogle ScholarPubMed
20.Hatzichristou, D, Moysidis, K, Apostolidis, A, et al.Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur Urol. 2005;47:518–523.CrossRefGoogle Scholar
21.Shepherd, JE. Therapeutic options in female sexual dysfunction. J Am Pharm Assoc. 2002;42:479–488.Google ScholarPubMed
22.Phillips, NA. Female sexual dysfunction: evaluation and treatment. Am Fam Physician. 2000;62:127–136, 141–142.Google ScholarPubMed
23.Ragucci, KR, Culhane, NS. Treatment of female sexual dysfunction. Ann Pharmacother. 2003;37:546–555.CrossRefGoogle ScholarPubMed
24.Buster, JE, Kingsberg, SA, Aguirre, O, et al.Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol. 2005;105:944–952.CrossRefGoogle ScholarPubMed
25.Kaplan, SA, Reis, RB, Kohn, IJet al.Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology. 1999;53:481–486.CrossRefGoogle ScholarPubMed
26.Caruso, S, Intelisano, G, Lupo, L, Agnello, C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. Br J Obstet Gynecol. 2001;108:623–628.Google ScholarPubMed
27.Kandeel, FR, Koussa, VKT, Swerdloff, RS. Male sexual dysfunction and its disorders: physiology, pathophysiology, clinical investigation, and treatment. Endocrine Rev. 2001;22:342–388.CrossRefGoogle ScholarPubMed
28.Nellans, RE, Ellis, LR, Kramer-Levien, D. Pharmacological erection: diagnosis and treatment applications in 69 patients. J Urol. 1987;138:52–54.CrossRefGoogle ScholarPubMed
29.VonHeyden, B, Donatucci, CF, Kaula, N, et al.Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose. J Urol. 1993;149:1288–1290.CrossRefGoogle Scholar
30.Fallon, B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin N Am. 1995;22:833–845.CrossRefGoogle ScholarPubMed
31.Hanash, KA. Comparative results of goal oriented therapy for erectile dysfunction. J Urol. 1997;157:2135–2138.CrossRefGoogle ScholarPubMed
32.Ernst, E, Pittler, MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol. 1998;159:433–436.CrossRefGoogle ScholarPubMed
33.Susset, JG, Tessier, CD, Wincze, J, et al.Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol. 1989;141:1360–1363.CrossRefGoogle ScholarPubMed
34.Teloken, C, Rhoden, EL, Sogari, P, et al.Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol. 1998;159:122–124.CrossRefGoogle ScholarPubMed
35.Gutierrez, MA, Stimmel, GL. Management of and counseling for psychotropic drug-induced sexual dysfunction. Pharmacotherapy. 1999;19:823–831.CrossRefGoogle ScholarPubMed
36.Montague, DK, Jarow, JP, Broderick, GA, et al.Erectile Dysfunction Guideline Update Panel. The Management of Erectile Dysfunction: an Update. Baltimore, Md: American Urological Association Education and Research, Inc; 2005.Google Scholar
37.Gresser, U, Gleiter, CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil. Eur J Med Res. 2002;7:435–446.Google ScholarPubMed
38.Campbell, HE. Clinical monograph for drug formulary review: erectile dysfunction agents. J Manag Care Pharm. 2005;11:151–171.Google ScholarPubMed
39.Snow, KJ. Erectile dysfunction: a review and update. Formulary. 2004;39:261–268.Google Scholar
40.Coleman, CI, Vergara, CM, Wang, F. Vardenafil. Formulary. 2003;38:131–148.Google Scholar
41.Brock, GB, McMahon, CG, Chen, KK, et al.Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168:1332–1336.CrossRefGoogle ScholarPubMed
42.Leiblum, SR. After sildenafil: bridging the gap between pharmacologic treatment and satisfying sexual relationships. J Clin Psychiatry. 2002;63(suppl 5):17–22.Google Scholar
43.Montague, DK, Jarow, J, Broderick, GA, et al.AUA guideline on the pharmacologic management of premature ejaculation. J Urol. 2004;172(1):290–294.CrossRefGoogle ScholarPubMed
44.Sharlip, I. Diagnosis and treatment of premature ejaculation: the physician's perspective. J Sex Med. 2005;2:103–109.CrossRefGoogle ScholarPubMed
45.Choi, HK, Jung, GW, Moon, KH, et al.Clinical study of SS-cream in patients with lifelong premature ejaculation. Urology. 2000;55:257–261.CrossRefGoogle ScholarPubMed
46.Althof, SE, Levine, SB, Corty, EW, et al.A double-blind crossover trial of clomipramine for rapid ejaculation in 15 couples. J Clin Psychiatry. 1995;56:402–407.Google ScholarPubMed
47.Waldinger, MD, Hengeveld, MW, Zwinderman, AH, Olivier, B. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol. 1998;18:274–281.CrossRefGoogle ScholarPubMed
48.Waldinger, MD, Olivier, B. Utility of selective serotonin reuptake inhibitors in premature ejaculation. Curr Opin Invest Drugs. 2004;5:743–747.Google ScholarPubMed
49.Herzog, AG, Klein, P, Jacobs, AR. Testosterone versus testosterone and testolactone in treating reproductive and sexual dysfunction in men with epilepsy and hypogonadism. Neurology. 1998;50:782–784.CrossRefGoogle ScholarPubMed
50.Harden, C, MacLusky, NJ. Aromatase inhibitors as add-on treatment for men with epilepsy. Expert Rev Neurother. 2005;5:123–127.CrossRefGoogle ScholarPubMed
51.Gilad, R, Lampl, Y, Eshel, Y, Sadeh, M. Tonic-clonic seizures in patients taking sildenafil [letter]. BMJ. 2002;325:869.CrossRefGoogle ScholarPubMed